Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Analysts at Oppenheimer

Equities researchers at Oppenheimer assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research note issued on Monday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $53.00 price target on the stock. Oppenheimer’s price objective suggests a potential upside of 48.42% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus boosted their price objective on Kymera Therapeutics from $35.00 to $55.00 and gave the company a “buy” rating in a report on Friday, February 23rd. Truist Financial lifted their price target on Kymera Therapeutics from $41.00 to $54.00 and gave the company a “buy” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. lifted their price target on Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Bank of America lowered Kymera Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $45.00 to $30.00 in a research note on Wednesday, January 3rd. Finally, Wolfe Research assumed coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating for the company. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $41.20.

Kymera Therapeutics Stock Up 4.0 %

Shares of KYMR stock opened at $35.71 on Monday. The stock has a market cap of $2.18 billion, a PE ratio of -14.17 and a beta of 2.27. The business has a 50-day simple moving average of $39.13 and a 200-day simple moving average of $28.33. Kymera Therapeutics has a 52-week low of $9.60 and a 52-week high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.19. The business had revenue of $47.90 million during the quarter, compared to analysts’ expectations of $41.94 million. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The company’s revenue for the quarter was up 197.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.60) EPS. Sell-side analysts anticipate that Kymera Therapeutics will post -3.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 139,255 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total transaction of $5,880,738.65. Following the completion of the sale, the director now directly owns 828,830 shares in the company, valued at approximately $35,001,490.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Kymera Therapeutics news, Director Bruce Booth sold 139,255 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $42.23, for a total transaction of $5,880,738.65. Following the completion of the sale, the director now directly owns 828,830 shares in the company, valued at approximately $35,001,490.90. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jared Gollob sold 46,137 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $35.50, for a total value of $1,637,863.50. Following the completion of the sale, the insider now owns 74,709 shares of the company’s stock, valued at $2,652,169.50. The disclosure for this sale can be found here. In the last three months, insiders sold 474,051 shares of company stock worth $19,624,211. Corporate insiders own 16.67% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its position in shares of Kymera Therapeutics by 33.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock valued at $72,000 after purchasing an additional 1,310 shares in the last quarter. Quest Partners LLC purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $78,000. Arizona State Retirement System purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $142,000. China Universal Asset Management Co. Ltd. grew its position in shares of Kymera Therapeutics by 352.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after purchasing an additional 5,002 shares in the last quarter. Finally, Hsbc Holdings PLC purchased a new stake in shares of Kymera Therapeutics in the third quarter valued at approximately $185,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.